Infections caused by the opportunistic pathogen Mycobacterium abscessus are increasing in 23 prevalence within the cystic fibrosis population. Our limited understanding of this ubiquitous 24 environmental microorganism matched with its intrinsic resistance to most classes of antibiotic, 25 including -lactams, has left us with an urgent demand for new, more effective therapeutic 26 interventions. De novo antimicrobial drug discovery is a lengthy process and so we have taken the 27 approach of repurposing known antibiotics in order to provide a rapidly implementable solution to a 28 current problem. Here we report a significant step forward in treatment potential for M. abscessus 29 infection by sensitising the organism to the broad spectrum -lactam antibiotic, amoxicillin, using the 30 non-competitive -lactamase inhibitor, relebactam. We demonstrate by disk diffusion and broth 31 microdilution assay that this combination works synergistically to inhibit M. abscessus. We also 32 demonstrate the direct non-competitive inhibition of the M. abscessus -lactamase, BlaMab using a 33 novel thin-layer chromatography-based assay for -lactamase inhibition, which is subsequently 34 kinetically validated by spectrophotometric assay using the nitrocefin reporter assay. 
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In order to further validate our observation, liquid cultures were exposed to increasing concentrations 186 of amoxicillin and meropenem with and without a dose response of relebactam (1e and 1f 187 respectively). As a control, relebactam was also tested for inhibitory activity on its own. These cultures 188 were read every 24 hours using a spectrophotometer at OD600nm up to 96 hours. 
